Advanced searches left 3/3

Amyotrophic Lateral Sclerosis - PLOS

Summarized by Plex Scholar
Last Updated: 27 June 2022

* If you want to update the article please login/register

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

In the phase 3 study MCI186-19, Edaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis. Objective: To discuss the efficacy of edaravone in ALS patients with FVC > 80%p. Methods: Study 19: A post-hoc review of Study 19 comparing edaravone efficacy in women with FVC24 80%p vs. 80%p. Through week 48, researchers in both the FVC24 u226580%p and the FVC24 80%p subgroups experienced a decrease in ALS Functional Rating Scale-Revised score loss vs placebo subjects after receiving edaravone therapy. For the FVC24 â€206580%p subgroup, the changes in ALSFRS-R ratings from baseline to week 48 were u22127. 63, a difference of 2. 05 points. Conclusion: ALS patients in the Study 19 placebo group showed a slowing in disease progression even before beginning edaravone with a FVC of 80%p.

Source link: https://doi.org/10.1371/journal.pone.0258614


Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

Amyotrophic lateral sclerosis (MDL) is a multisystem neurodegenerative disorder with progressive degeneration of upper motor neurons and lower motor neurons, as well as frontotemporal regions, resulting in impaired bulbar, leg, and cognitive function. Cortical and subcortical brain involvement in ALS pathophysiology has been confirmed in magnetic resonance imaging studies. Through the Canadian ALS Neuroimaging Consortium, a total of 235 subjects 120 ALS patients were recruited across North America; 115 healthy controls were recruited across North America; 115 healthy controls were recruited across North America. Patients with ALS, right and left fronto-parietal, and orbitofrontal RSNs, as well as other previously undescribed networks such as auditory, dorsal attention, medial temporal, ventral streams, and cerebellum, which were positively related to disease severity, exhibited higher intra-network Rs-FC in the sensorimotor, default mode, right and left fronto-parietal, ventral, and cerebellum were shown to raise intra-FC In addition, ALS patients showed increased intra-network Rs-FC between the orbitofrontal and basal ganglia RSNs, which negatively related to cognitive impairment.

Source link: https://doi.org/10.1371/journal.pone.0269154

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions